Table 4

HIV-1 patient information and CTL responses to peptide pools

PATIENT INFORMATION
 CTL RESPONSES TO PEPTIDE POOLS AS DETERMINED BY INTERFERON-GAMMA ELISPOT (SFC*)
PATIEND ID
 HLA TYPE
 DISEASE STAGE*
 HAART*
 ON HAART SINCE
 INFECTED SINCE
 VL*
 PBMC DATE*
 Pool 1
 Pool 1
 Pool 2
 Pool 2
 Pool 3
 Pool 3
 Pool 4
 Pool 4
 Pool 5
 Pool 5
 CEF*
 NEG
 NEG
 NEG
 POS
1
 Unavailable
 Unavailable
 Unavailable
 NA
 Unavailable
 Unavailable
 6/22/04
 1860
 1610
 530
 510
 700
 620
 10
 10
 10
 10
 0
 0
 0
 0
 PPP
2
 Unavailable
 Unavailable
 Unavailable
 NA
 Unavailable
 Unavailable
 2/17/04
 910
 960
 20
 0
 40
 40
 0
 0
 10
 10
 0
 20
 0
 0
 PPP
3
 Unavailable
 Chronic
 No
 NA
 Unknown
 >750000
 2/19/04
 0
 0
 0
 10
 0
 0
 0
 0
 0
 0
 675
 0
 0
 0
 PP
4
 Unavailable
 Chronic
 No
 NA
 Unknown
 >750000
 2/26/04
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 70
 0
 0
 0
 PPP
5
 Unavailable
 Chronic
 No
 NA
 Unknown
 12905
 3/4/04
 110
 150
 60
 80
 90
 70
 50
 30
 30
 40
 266
 60
 40
 50
 PPP
6
 Unavailable
 Chronic
 Yes
 4/18/01
 Unknown
 176
 2/26/04
 180
 130
 150
 200
 150
 150
 210
 250
 100
 120
 163
 0
 0
 0
 PPP
7
 Unavailable
 Chronic
 Yes
 1/26/03
 Unknown
 6030
 2/19/04
 0
 0
 0
 0
 0
 0
 0
 0
 0
 10
 60
 0
 0
 0
 PPP
8
 Unavailable
 Chronic
 Yes
 NA
 Unknown
 >750000
 2/24/04
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 >1000
 0
 0
 0
 PPP
9
 Unavailable
 Chronic
 No
 NA
 Unknown
 >500000
 2/19/04
 0
 0
 10
 0
 30
 20
 170
 150
 0
 0
 540
 0
 0
 0
 PP
10
 Unavailable
 Chronic
 No
 NA
 Unknown
 35100
 2/26/04
 1440
 1010
 1010
 760
 1040
 1070
 1050
 1080
 1270
 1160
 >1000
 10
 20
 40
 PPP
11
 Unavailable
 Chronic
 No
 NA
 Unknown
 236000
 3/2/04
 10
 10
 30
 30
 20
 20
 30
 30
 30
 40
 20
 10
 30
 10
 PPP
12
 Unavailable
 Chronic
 No
 NA
 Unknown
 9030
 2/19/04
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 140
 0
 0
 0
 PP
13
 Unavailable
 Chronic
 No
 NA
 Unknown
 12000
 3/4/04
 260
 210
 190
 160
 180
 210
 150
 210
 150
 160
 >1000
 10
 20
 0
 PPP
14
 A11/74, B35/44, C4/5
 Chronic
 No
 NA
 Unknown
 74
 4/20/04
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 833
 0
 0
 0
 PPP
15
 A30/33, B13/14, C5/8
 Chronic
 No
 NA
 Unknown
 122
 4/20/04
 60
 90
 20
 0
 20
 10
 20
 10
 20
 20
 0
 0
 10
 10
 PPP
16
 A25/32, B18/40, C2/12
 Chronic
 No
 NA
 Unknown
 12700
 4/20/04
 420
 410
 340
 350
 220
 370
 550
 490
 620
 500
 0
 10
 10
 0
 PPP
17
 a2/30, b44/57, c5/18
 Chronic
 No
 NA
 Unknown
 49
 4/27/04
 380
 380
 420
 470
 330
 410
 490
 500
 360
 250
 953
 0
 0
 0
 PPP
18
 A1/74, B57/81, C7/18
 Chronic
 No
 NA
 Unknown
 845
 6/3/04
 0
 20
 0
 20
 10
 10
 10
 0
 20
 20 ND
 0
 0
10
 PP
19
 A3/33, B15/49, C7/14
 Chronic
 No
 NA
 Unknown
 49
 6/16/04
 350
 350
 170
 140
 230
 270
 220
 240
 110
 90 ND
 0
 0
10
 PPP
20
 A29, B44, C16
 Chronic
 No
 NA
 Unknown
 807
 6/16/04
 210
 180
 130
 180
 200
 260
 0
 20
 0
 0 ND
 0
 10
0
 PPP
21
 A1/24, B13/57, C6
 Acute
 No
 NA
 Unknown
 5490
 6/22/04
 130
 120
 110
 120
 270
 230
 0
 0
 0
 0
 60
 0
 10
 0
 PPP
22
 A1/24, B8/35, C4/7
 Acute
 Yes
 7/21/03
 2002, May
 <50
 2/17/04
 130
 100
 30
 50
 70
 40
 120
 100
 70
 50
 347
 0
 0
 0
 PPP
23
 A24/32, B35/41, C4/17
 Acute
 Yes
 6/1/02
 2002, Jun
 <50
 2/19/04
 0
 0
 0
 0
 0
 0
 260
 300
 200
 140
 146
 0
 0
 10
 PPP
24
 A2/31, B40/44, C3/16
 Acute
 Yes
 9/2/03
 2003, Aug
 <400
 2/26/04
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 440
 0
 0
 0
 PPP
25
 A11/30, B15/35, C3/4
 Acute
 Yes
 12/30/03
 2003, Dec
 <400
 2/26/04
 20
 30
 10
 30
 20
 30
 30
 40
 10
 30
 396
 20
 0
 20
 PPP
26
 A11/24, B35/38, C4/7
 Acute
 Yes
 5/19/99
 1999, may
 <50
 3/1/04
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 60
 0
 20
 0
 PPP
27
 A1/24, B14/35, C4/8
 Acute
 Yes
 9/8/03
 2003, JUL
 <400
 3/1/04
 40
 50
 40
 30
 30
 60
 10
 50
 30
 10
 100
 0
 0
 20
 PPP
28
 A1/11, B18/52, C12
 Acute
 Yes
 8/25/99
 1999, SEP
 <50
 3/9/04
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 520
 0
 0
 0
 PPP
29
 A3/68, B14/44, B8/16
 Acute
 Yes
 9/2/03
 2003, AUG
 <50
 3/9/04
 250
 320
 50
 50
 40
 20
 0
 0
 20
 20
 140
 0
 0
 0
 PPP
30
 A1/32, B7/44, C7/16
 Acute
 Yes
 2/18/04
 2004, FEB
 5,440
 4/20/04
 40
 20
 100
 90
 120
 110
 170
 120
 180
 220
 433
 0
 0
 0
 PPP
31
 A2/3, B7/44, C5/7
 Acute
 Yes
 8/1/97
 1997-AUG
 149
 4/20/04
 20
 0
 0
 0
 0
 0
 10
 0
 0
 0
 443
 0
 10
 0
 PP
32
 A33, B53, C4
 Acute
 Yes
 12/14/00
 2000-NOV
 <50
 4/22/04
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 PPP
33
 A1/68, B7/8, C7/7
 Acute
 Yes
 4/23/04
 2004-APR
 853
 5/6/04
 10
 10
 0
 0
 0
 0
 0
 10
 0
 0
 ND
 0
 0
 0
 PPP
34
 A3/24, B40/57, C3/7
 Acute
 Yes
 11/5/03
 2003-NOV
 <50
 5/12/04
 220
 170
 190
 170
 190
 120
 10
 30
 0
 10
 0
 30
 10
 20
 PPP
35
 A26/68, B44/71, C3/7
 Acute
 Yes
 12/22/98
 1996-NOV
 <50
 5/13/04
 0
 0
 0
 20
 10
 10
 0
 10
 10
 10
 20
 10
 10
 10
 PPP
36
 A2/26, B53/57, C4/18
 Acute
 Yes
 5/24/01
 2001, MAY
 <400
 6/23/04
 0
 0
 0
 0
 0
 10
 0
 0
 0
 0
 0
 0
 10
 0
 PPP
37
 A2/74, B51/53, C4/14
 Acute
 Yes
 8/22/01
 2001, AUG
 <50
 6/22/04
 0
 10
 0
 10
 20
 20
 0
 20
 0
 10
 986
 0
 0
 0
 PPP
38
 A1/2, B8/15, C3/7
 Acute
 Yes
 3/9/99
 1999, MAR
 1,111
 5/19/04
 420
 430
 480
 420
 500
 410
 430
 410
 430
 480
 326
 0
 0
 0
 PPP
39
 A1/2, B7/8, C7/7
 Acute
 No
 7/22/02
 2002, JUL
 <400
 3/2/04
 10
 20
 10
 10
 0
 10
 10
 0
 0
 10
 >1000
 0
 0
 10
 PPP
40
 A23/24, B44/60, C3/14
 Acute
 No
 NA
 2004, FEB
 1,580
 3/15/04
 210
 220
 90
 90
 80
 100
 0
 0
 0
 0
 70
 0
 20
 0
 PPP
41
 A1/3, B8/15, C7
 Acute
 No
 NA
 2003, AUG
 56,100
 4/14/04
 260
 210
 380
 480
 360
 290
 300
 430
 430
 440
 ND
 0
 0
 0
 PPP
42
 A2/31, B15/51, C3/15
 Acute
 No
 NA
 2003-MAY
 2,620
 6/3/04
 410
 430
 480
 410
 490
 430
 440
 410
 400
 470
 116
 0
 0
 20
 PPP
43
 A3/24, B14/35, C8/12
 Acute
 No
 NA
 2000-MAY
 883
 5/26/04
 250
 250
 40
 30
 20
 40
 40
 40
 40
 30
 80
 0
 0
 10
 PPP
44
 A1/3, B35/40, C4/15
 Acute
 No
 NA
 2003-OCT
 121,000
 5/13/04
 910
 1150
 1010
 1010
 1100
 1080
 980
 1330
 930
 1090
 260
 0
 0
 0
 PPP
45
 A3/41, B14/35, C8/12
 Acute
 No
 NA
 2002, FEB
 29,000
 6/22/04
 950
 1090
 30
 40
 40
 60
 40
 40
 50
 60
 143
 0
 0
 0
 PPP
46
 A2/32, B15/39, C4/15
 Acute
 No
 NA
 2001, OCT
 48,000
 6/23/04
 1200
 1200
 1150
 1460
 1660
 1300
 1460
 1290
 1390
 1540
 160
 0
 10
 10
 PPP
47
 A3/68, B35/44, C4/7
 Acute
 No
 NA
 1999, AUG
 667
 5/26/04
 10
 30
 0
 30
 10
 20
 0
 20
 10
 0
 ND
 0
 20
 10
 PPP

CTL responses were determined by the interferon-gamma elispot assay

SFC*: Spot Forming Colonies

DISEASE STAGE*: refers to the stage at the time of diagnosis

HAART*: Patients were receiving HAART treatment at the time of PBMC collection

VL*: Viral Load at the time of PBMC sampling in copies/ml

PBMC DATE*: Date PBMC samples were collected

CEF: Response to CMV, EBV and Influenza A peptide pools.

POS is a PHA response where PP = high and PPP = highest responses related to non-stimulated controls. Both PP and PPP are equivalent to responses form normal individuals.

NA, Not Applicable

Reche et al. Medical Immunology 2006 5:1   doi:10.1186/1476-9433-5-1